Change in Modulight Corporation’s holding of treasury shares and annulment of option rights

Modulight Corporation issued 815,859 new shares and 852,758 option rights to its employees in a personnel share issue in September 2021. The issuance of shares was carried out in deviation from shareholders’ pre-emptive right (directed issue) in order to engage and retain employees.
 
Modulight Corporation has acquired a total of 51,123 shares subscribed in the personnel share issue from an employee whose employment with Modulight Corporation has ended, in accordance with the terms and conditions of the directed share issue. The purchase price is EUR 0.32 per share, which is the original subscription price. In addition, Modulight Corporation annuls 62,364 option rights which have been returned to the possession of Modulight Corporation due to an ended employment.
 
The shares were acquired on 29 September 2023. After the acquisition, Modulight Corporation holds a total of 51,123 treasury shares. After the annulment of the option rights, Modulight Corporation does not hold any option rights.
 
MODULIGHT CORPORATION
 
For further information, please contact:
 
CEO: Seppo Orsila, m. +358 40 830 4671
 
IR: Ulla Haapanen, m. +358 40 830 4676
Email: [email protected]
 
Certified Adviser:
Danske Bank A/S, Finland Branch, m. +358 40 414 5358
 
www.modulight.com
Twitter: @modulight, @orsila

Modulight in brief
 
Modulight Corporation is a biomedical laser company that designs and manufactures products for oncology, ophthalmology and genetics. The company also provides solutions for selected high value-add applications including quantum computing and digital press. The company’s products include medical devices, subsystems, software, cloud services and specialized semiconductors. Modulight’s products are used worldwide by many Fortune 500 companies, pharmaceutical companies, and well-known cancer centers and universities. Modulight was founded in 2000 and is headquartered in Tampere, Finland. www.modulight.com